What is Innovate's life sciences — accounts payable?

Innovate (VATE) reported life sciences — accounts payable of $200K in Q1 2026.

What does life sciences — accounts payable mean?

This represents the total amount the Life Sciences segment owes to suppliers and vendors for goods or services received on credit. It is a primary indicator of the segment's short-term liabilities and its management of working capital cycles.

Innovate VATE Life Sciences — Accounts Payable

Similar metrics at other companies

NGLLiquids Logistics — Accounts Payable

$0—

EXELAccounts Payable

$24.15M-43.6%

CAHAccounts Payable

$37.83B+15.3%

MANEAccounts Payable

$1.07M+256%

SMMTAccounts Payable

$27.55M+452%

TGTXAccounts Payable

$148.85M+11.1%

Other financials

Income statement

See full

Revenue$364.8M+33.0%

Gross profit$53.5M+17.6%

Operating income$10.0M+194%

Net income-$16.8M+31.4%

EPS (diluted)-$1.29+31.7%

Balance sheet

See full

Cash & equivalents$134.6M+297%

Total debt$1.4B+11.6%

Total equity-$256.3M-25.5%

Total assets$936.8M+7.9%

Cash flow

See full

Operating cash flow$45.5M+423%

CapEx$200.0K-95.7%

Free cash flow$45.3M+341%

Valuation

See full

Market cap$254.69M+274%

Enterprise value$1.52B+25.8%

P/S0.2×+0.1×

Profitability

See full

Gross margin15.5%-3.8pp

Operating margin2.6%-1.2pp

Net margin-4%0.0pp

FCF margin15.7%—

Returns & leverage

See full

Return on equity-8.1%—

Debt / equity1.7×—

Current ratio0.4×0.0×

Where this comes from

Reported directly by Innovate in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableAndOtherAccruedLiabilities.

The official record: Innovate’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innovate's life sciences — accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Innovate's life sciences — accounts payable?: Innovate (VATE) reported life sciences — accounts payable of $200K in Q1 2026.
What does life sciences — accounts payable mean?: This represents the total amount the Life Sciences segment owes to suppliers and vendors for goods or services received on credit. It is a primary indicator of the segment's short-term liabilities and its management of working capital cycles.